Voyager Therapeutics Inc., of Cambridge, Mass., reported interim surgical results from an ongoing phase Ib study of VY-AADC01 in patients with advanced Parkinson's disease at the International Congress of Parkinson's Disease and Movement Disorders in Berlin.